• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jeffrey G. Supko, PhD

Publications

  • Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE.Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib.Cancer Discovery. 2014 Mar 27.
    24625776
  • Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX.Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.Cancer Chemother Pharmacol. 2013 Dec;72(6):1305-14.
    24121453
  • Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP.Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.Blood. 2013 Jul 25;122(4):507-14.
    23741010
  • Brown JR, Messmer BT, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, Lacasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS.A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia / small lymphocytic lymphoma.Haematologica. 2013 May 3.
    23645694
  • Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS.Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.Oncologist. 2013 Apr 11.
    23580238
  • Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S.A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.Clin Cancer Res. 2013 Apr 1;19(7):1873-83.
    23515411
  • Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, Nabors LB, Rosenfeld MR, Mikkelsen T, Grossman SA, .NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.Neuro Oncology. 2013 Apr;15(4):490-6.
    23328813
  • Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdière C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, Silverman LB.Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.J Clin Oncol. 2013 Mar 20;31(9):1202-10.
    23358966
  • Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG.Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.Clin Cancer Res. 2013 Mar 15;19(6):1557-66.
    23362324
  • Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG, Hochberg F.A phase II trial of oral gimatecan for recurrent glioblastoma.J. Neurooncol. 2013 Feb;111(3):347-53.
    23232808
  • Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV.A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.J Thorac Oncol. 2012 Oct;7(10):1602-8.
    22878749
  • Chen L, Aktas BH, Wang Y, He X, Sahoo R, Zhang N, Denoyelle S, Kabha E, Yang H, Freedman RY, Supko JG, Chorev M, Wagner G, Halperin JA.Tumor suppression by small molecule inhibitors of translation initiation.Oncotarget. 2012 Aug;3(8):869-81.
    22935625
  • Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ.A phase i first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.Clin Cancer Res. 2012 Jun 15;18(12):3396-406.
    22634319
  • Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko JG, Kharbanda S, Kufe DW.DEPENDENCE ON THE MUC1-C ONCOPROTEIN IN NON-SMALL CELL LUNG CANCER CELLS WITH EGFR AND K-RAS MUTATIONS.Mol Cancer Ther. 2011 Mar 18.
    21421804
  • Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelson T, Fisher J, Desideri S, He X, Grossman SA, .A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.J. Neurooncol. 2010 Nov;100(2):261-8.
    20449631
  • Phuphanich S, Supko JG, Carson KA, Grossman SA, Burt Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson JJ.Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.J. Neurooncol. 2010 Oct;100(1):95-103.
    20213332
  • Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD.Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8.
    20660316
  • Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Fisher J, Desideri S, He X, Grossman SA, .Erratum to: A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.J. Neurooncol. 2010 Jun 1.
    20514550
  • Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, Cao B, Olivi A, Grossman SA.Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme.J. Neurooncol. 2010 Apr;97(2):241-5.
    19768386
  • Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Laverdière C, Michon B, Schorin M, Schwartz CL, O'Brien JE, Cohen HJ, Sallan SE.Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.Blood. 2010 Feb 18;115(7):1351-3.
    20007809
  • Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, Kelly KM, Laverdière C, Michon B, Schorin M, Cohen HJ, Sallan SE, Silverman LB.Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.Pediatr Blood Cancer. 2010 Feb;54(2):199-205.
    19672973
  • Fidias P, Pennell NA, Boral AL, Shapiro GI, Skarin AT, Eder JP, Kwoh TJ, Geary RS, Johnson BE, Lynch TJ, Supko JG.Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.J Thorac Oncol. 2009 Sep;4(9):1156-62.
    19704336
  • Zhu AX,Ready N,Clark JW,Safran H,Amato A,Salem N,Pace S,He X,Zvereva N,Lynch TJ,Ryan DP,Supko JG.Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.Clin Cancer Res. 2009 Jan 1;15(1):374-81.
    19118068
  • Kieran MW,Supko JG,Wallace D,Fruscio R,Poussaint TY,Phillips P,Pollack I,Packer R,Boyett JM,Blaney S,Banerjee A,Geyer R,Friedman H,Goldman S,Kun LE,Macdonald T.Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.Pediatr Blood Cancer. 2009 Feb;52(2):169-76.
    19065567
  • Blakeley JO,Olson J,Grossman SA,He X,Weingart J,Supko JG.Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study.J Neurooncol. 2009 Jan;91(1):51-8.
    18787762
  • Grossman SA,Carson KA,Phuphanich S,Batchelor T,Peereboom D,Nabors LB,Lesser G,Hausheer F,Supko JG.Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.Neuro-oncol. 2008 Aug;10(4):608-16.
    18577560
  • Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC.Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.Clin Cancer Res. 2008 Mar 1;14(5):1446-54.
    18316568
  • Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG.Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.Neuro-oncol. 2008 Apr;10(2):190-8.
    18287342
  • Miao XS,Song P,Savage RE,Zhong C,Yang RY,Kizer D,Wu H,Volckova E,Ashwell MA,Supko JG,He X,Chan TC.Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; beta-lapachone) in whole blood.Drug Metab Dispos. 2008 Apr;36(4):641-8.
    18180274
  • McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.
    18077425
  • Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS.Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.Cancer Chemother Pharmacol. 2007 Oct;60(5):661-70.
    17216531
  • Akingbemi BT,Braden TD,Kemppainen BW,Hancock KD,Sherrill JD,Cook SJ,He X,Supko JG.Exposure to phytoestrogens in the perinatal period affects androgen secretion by testicular Leydig cells in the adult rat.Endocrinology. 2007 Sep;148(9):4475-88.
    17569756
  • Srouji SS, Pagán YL, D'Amato F, Dabela A, Jimenez Y, Supko JG, Hall JE.Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome.J Clin Endocrinol Metab. 2007 Apr;92(4):1347-52.
    17264175
  • Berkenblit A, Eder JP, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, Dahl TA, Dezube BJ, Supko JG.Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):584-90.
    17255281
  • Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC.A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.Cancer. 2006 Dec 1;107(11):2688-97.
    17075878
  • Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J, Eder JP.Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.Cancer. 2006 Nov 15;107(10):2482-9.
    17036355
  • Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG.The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.Clin Cancer Res. 2006 Sep 1;12(17):5174-81.
    16951236
  • Krasner CN, Roche M, Horowitz NS, Supko JG, Lee SI, Oliva E.Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.N Engl J Med. 2006 Apr 13;354(15):1615-25.
    16611953
  • Klein A, He X, Roche M, Mallett A, Duska L, Supko JG, Seiden MV.Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.Gynecol Oncol. 2006 Jan;100(1):205-9.
    16171852
  • Eder JP, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG.Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.Cancer Chemother Pharmacol. 2006 Jul;58(1):107-116.
    16362299
  • Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, Colevas AD, Posner MR, Deschler DG, Rocco JW, Finkelstein DM, McIntyre JF.Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.Cancer. 2005 Oct 1;104(7):1418-27.
    16116597
  • Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD.Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.J Clin Oncol. 2005 Aug 20;23(24):5484-92.
    16110008
  • Goffin JR, Anderson IC, Supko JG, Eder JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT.Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.Clin Cancer Res. 2005 May 1;11(9):3417-24.
    15867243
  • Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr FA, Grundy JS, Holmlund JT.Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.Neuro-oncol. 2005 Jan;7(1):32-40.
    15701280
  • Lau L, Supko JG, Blaney S, Hershon L, Seibel N, Krailo M, Qu W, Malkin D, Jimeno J, Bernstein M, Baruchel S.A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):672-7.
    15701855
  • Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP.Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.Int J Cancer. 2005 Jan 20;113(3):490-8.
    15455390
  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med. 2004 May 20;350(21):2129-39.
    15118073
  • Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD.Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.J Clin Oncol. 2004 Apr 15;22(8):1480-90.
    15084621
  • Ryan DP, Eder JP, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, Clark JW.Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.Clin Cancer Res. 2004 Apr 1;10(7):2222-30.
    15073096
  • Zhu AX, Puchalski TA, Stanton VP, Ryan DP, Clark JW, Nesbitt S, Charlat O, Kelly P, Kreconus E, Chabner BA, Supko JG.Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.Clin Colorectal Cancer. 2004 Feb;3(4):225-34.
    15025795
  • Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T, Phuphanich S,.Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.Neuro-oncol. 2004 Jan;6(1):21-7.
    14769136
  • Eder JP, Garcia-Carbonero R, Clark JW, Supko JG, Puchalski TA, Ryan DP, Deluca P, Wozniak A, Campbell A, Rothermel J, LoRusso P.A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-Fluorouracil in patients with advanced solid malignancies.Invest New Drugs. 2004 Apr;22(2):139-50.
    14739662
  • He X, Batchelor TT, Grossman S, Supko JG.Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 25;799(2):281-91.
    14670747
  • Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.Clin Cancer Res. 2003 Nov 1;9(14):5178-86.
    14613997
  • Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF, Wilson KS, Puchalski TA, Supko JG, Seiden MV.Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mllerian tumors.Gynecol Oncol. 2003 Sep;90(3):610-8.
    13678734
  • Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S.Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.Clin Cancer Res. 2003 Aug 1;9(8):2940-9.
    12912940
  • Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvos AG, Goorin AM, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D.Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.Cancer. 2003 Aug 15;98(4):832-40.
    12910529
  • Ryan DP, Puchalski T, Supko JG, Harmon D, Maki R, Garcia-Carbonero R, Kuhlman C, Winkelman J, Merriam P, Quigley T, Jimeno J, Manola J, Demetri GD.A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.Oncologist. 2002;7(6):531-8.
    12490740
  • Michaelson MD, Ryan DP, Fuchs CS, Supko JG, Garcia-Carbonero R, Paul Eder J, Clark JW.A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.Cancer. 2003 Jan 1;97(1):148-54.
    12491516
  • Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG.Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19.
    12357306
  • Stokvis E, Rosing H, Lpez-Lzaro L, Rodriguez I, Jimeno JM, Supko JG, Schellens JH, Beijnen JH.Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.J Mass Spectrom. 2002 Sep;37(9):992-1000.
    12271442
  • Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW.Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.J Clin Oncol. 2002 Sep 15;20(18):3772-84.
    12228197
  • Garcia-Carbonero R, Supko JG.Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.Clin Cancer Res. 2002 Mar;8(3):641-61.
    11895891
  • Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP.A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.Clin Cancer Res. 2002 Mar;8(3):691-7.
    11895897
  • Bunnell CA, Supko JG, Eder JP, Clark JW, Lynch TJ, Kufe DW, Shulman LN.Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.Cancer Chemother Pharmacol. 2001 Nov;48(5):347-55.
    11761451
  • Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ.A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.Clin Cancer Res. 2001 Dec;7(12):3942-9.
    11751486
  • Supko JG, Garcia-Carbonero R, Puchalski TA, Malspeis L.Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.Cancer Chemother Pharmacol. 2001 Sep;48(3):202-8.
    11592341
  • Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA.A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Mllerian tumors.Cancer. 2001 Sep 1;92(5):1156-67.
    11571729
  • Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ, Rollins BJ.A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.Clin Cancer Res. 2001 Jun;7(6):1590-9.
    11410495
  • Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV.The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.Gynecol Oncol. 2001 May;81(2):206-12.
    11330951
  • Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW.Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.Clin Cancer Res. 2001 Feb;7(2):231-42.
    11234874
  • Ciordia R, Supko J, Gatineau M, Batchelor T.Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing.Curr Oncol Rep. 2000 Sep;2(5):445-53.
    11122877
  • Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP.A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion.Cancer Chemother Pharmacol. 2000;46(4):319-28.
    11052630
  • Phillips LR, Malspeis L, Tubbs EK, Supko JG.Characterization of a novel degradation product of 2,2'-dithiobis[N-isoleucylbenzamide], an inhibitor of HIV nucleocapsid protein zinc fingers.J Pharm Biomed Anal. 2000 Aug 15;23(2-3):395-402.
    10933532
  • Supko JG, Nair RV, Seiden MV, Lu H.Adaptation of solid phase extraction to an automated column switching method for online sample cleanup as the basis of a facile and sensitive high-performance liquid chromatographic assay for paclitaxel in human plasma.J Pharm Biomed Anal. 1999 Dec;21(5):1025-36.
    10703971
  • Duska LR, Penson R, Supko JG, Finkelstein DM, Makastorsis T, Gallagher J, Borden K, Goodman A, Fuller AF, Nikrui N, Seiden MV.A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.Clin Cancer Res. 1999 Jun;5(6):1299-305.
    10389912
  • Sharpless JL, Supko JG, Martin KA, Hall JE.Disappearance of endogenous luteinizing hormone is prolonged in postmenopausal women.J Clin Endocrinol Metab. 1999 Feb;84(2):688-94.
    10022439
  • Phillips LR, Wolfe TL, Malspeis L, Supko JG.Analysis of brefeldin A and the prodrug breflate in plasma by gas chromatography with mass selective detection.J Pharm Biomed Anal. 1998 Apr;16(8):1301-9.
    9777604
  • Supko JG, Soglia JR, Nair RV.Assay for the quinocarmycin analog DX-52-1 in human plasma using high-performance liquid chromatography with automated column switching and low wavelength ultraviolet detection.J Chromatogr B Biomed Sci Appl. 1998 Sep 4;714(2):341-53.
    9766875
  • Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G, Kufe DW.Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.Clin Cancer Res. 1998 Feb;4(2):317-24.
    9516917
  • Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW.Trials of 9-amino-20(S)-camptothecin in Boston.Ann N Y Acad Sci. 1996 Dec 13;803:247-55.
    8993518
  • Supko JG, Phillips LR, Malspeis L.Specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea in plasma.J Chromatogr B Biomed Appl. 1996 Mar 3;677(2):351-62.
    8704941
  • Rice WG, Supko JG, Malspeis L, Buckheit RW, Clanton D, Bu M, Graham L, Schaeffer CA, Turpin JA, Domagala J, Gogliotti R, Bader JP, Halliday SM, Coren L, Sowder RC, Arthur LO, Henderson LE.Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS.Science. 1995 Nov 17;270(5239):1194-7.
    7502043
  • Phillips LR, Malspeis L, Supko JG.Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog.Drug Metab Dispos. 1995 Jul;23(7):676-80.
    7587953
  • Burger AM, Kaur G, Alley MC, Supko JG, Malspeis L, Grever MR, Sausville EA.Tyrphostin AG17, [(3,5-Di-tert-butyl-4-hydroxybenzylidene)- malononitrile], inhibits cell growth by disrupting mitochondria.Cancer Res. 1995 Jul 1;55(13):2794-9.
    7796405
  • Supko JG, Phillips LR.High-performance liquid chromatographic assay for genistein in biological fluids.J Chromatogr B Biomed Appl. 1995 Apr 7;666(1):157-67.
    7655614
  • Supko JG, Hickman RL, Grever MR, Malspeis L.Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.Cancer Chemother Pharmacol. 1995;36(4):305-15.
    7628050
  • Supko JG, Malspeis L.Pharmacokinetics of michellamine B, a naphthylisoquinoline alkaloid with in vitro activity against human immunodeficiency virus types 1 and 2, in the mouse and dog.Antimicrob Agents Chemother. 1995 Jan;39(1):9-14.
    7695336
  • Supko JG, Malspeis L.Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse.Cancer Chemother Pharmacol. 1994;33(4):325-30.
    8281627
  • Supko JG, Malspeis L.Determination of michellamine B in biological fluids by high-performance liquid chromatography with fluorescence detection.Anal Biochem. 1994 Jan;216(1):52-60.
    8135366
  • Supko JG, Balcerzak SP, Kraut EH.Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.Cancer Res. 1993 Oct 15;53(20):4843-9.
    8402671
  • Supko JG, Malspeis L.Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice.Cancer Res. 1993 Jul 1;53(13):3062-9.
    8319213
  • Phillips LR, Supko JG, Malspeis L.Analysis of brefeldin A in plasma by gas chromatography with electron capture detection.Anal Biochem. 1993 May 15;211(1):16-22.
    8323029
  • Supko JG, Malspeis L.Liquid Chromatographic Analysis of 9-Aminocamptothecin in Plasma Monitored by Fluorescence Induced upon Postcolumn Acidification.Eval & Prog Plan. 1992;15:3261-3283.
  • Supko JG, Malspeis L.A Reversed-Phase HPLC Method for Determining Camptothecin in Plasma with Specificity for the Intact Lactone Form of the Drug.Eval & Prog Plan. 1991;14:1779-1803.
  • Supko JG, Malspeis L.Characterization of the urinary metabolites of merbarone in cancer patients.Drug Metab Dispos. 1991 Jan-Feb;19(1):263-73.
    1673412